Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 689-697

  Foroni, Chiara ^a   Broggini, Massimo ^b   Generali, Daniele ^a   Damia, Giovanna ^b  

^a CREMONA HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Breast cancer; Cancer stem cell; Epidermal mesenchymal transition

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR ALPHA; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; IMD 0354; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; OT 304; PACLITAXEL; PERIFOSINE; PIMASERTIB; PLATINUM DERIVATIVE; TAMOXIFEN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN; VINCA ALKALOID; XL 765;

BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL JUNCTION; CELL POPULATION; CIRCULATING TUMOR CELL; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; MESENCHYME CELL; METASTASIS; MICROENVIRONMENT; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; SIGNAL TRANSDUCTION;

EID: 84861676291     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.001     Document Type: Review

References (120)

1. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
2. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009, 119:1438-1449.
3. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46.
4. Al-Ejeh F., Smart C.E., Morrison B.J., Chenevix-Trench G., Lopez J.A., Lakhani S.R., et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011, 32:650-658.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
6. Arima Y., Inoue Y., Shibata T., Hayashi H., Nagano O., Saya H., et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008, 68:5104-5112.
7. Baffa R., Fassan M., Volinia S., O'Hara B., Liu C.G., Palazzo J.P., et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009, 219:214-221.
8. Bailey J.M., Singh P.K., Hollingsworth M.A. Cancer metastasis facilitated by developmental pathways: sonic hedgehog, notch, and bone morphogenic proteins. J Cell Biochem 2007, 102:829-839.
9. Baum B., Settleman J., Quinlan M.P. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008, 19:294-308.
10. Blanco M.J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J., et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21:3241-3246.
11. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S.A., et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:235-252.
12. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011, 30:770-782.
13. Buijs J., Henriquez N., van Overveld P., van der Horst G., ten Dijke P., van der Pluijm G. TGF-β and BMP7 interactions in tumour progression and bone metastasis. Clin Experiment Metastasis 2007, 24:609-617.
14. Buijs J.T., Petersen M., van der Horst G., van der Pluijm G. Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?. Curr Pharm Des 2010, 16:1291-1300.
15. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589.
16. Castilla M.Á., Moreno-Bueno G., Romero-Pérez L., De Vijver K.V., Biscuola M., López-García M.Á., et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011, 223:72-80.
17. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
18. Cheng G.Z., Chan J., Wang Q., Zhang W., Sun C.D., Wang L.-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67:1979-1987.
19. Chung J.H., Rho J.K., Xu X., Lee J.S., Yoon H.I., Lee C.T., et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2010, 73:176-182.
20. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055-1066.
21. Come C., Magnino F., Bibeau F., De Santa Barbara P., Becker K.F., Theillet C., et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006, 12:5395-5402.
22. Corcoran K.E., Trzaska K.A., Fernandes H., Bryan M., Taborga M., Srinivas V., et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One 2008, 3:e2563.
23. Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:253-260.
24. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106:13820-13825.
25. Cripe T.P., Wang P.Y., Marcato P., Mahller Y.Y., Lee P.W. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009, 17:1677-1682.
26. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
27. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Joven J., Menendez J.A. Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010, 9:4461-4468.
28. Damonte P., Gregg J.P., Borowsky A.D., Keister B.A., Cardiff R.D. EMT tumorigenesis in the mouse mammary gland. Lab Invest 2007, 87:1218-1226.
29. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4:e6896.
30. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E.F., Wallwiener D., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59.
31. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25.
32. Franci C., Takkunen M., Dave N., Alameda F., Gomez S., Rodriguez R., et al. Expression of Snail protein in tumor-stroma interface. Oncogene 2006, 25:5134-5144.
33. Gal A., Sjoblom T., Fedorova L., Imreh S., Beug H., Moustakas A. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 2008, 27:1218-1230.
34. Gebeshuber C.A., Zatloukal K., Martinez J. MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009, 10:400-405.
35. Gee H.E., Camps C., Buffa F.M., Colella S., Sheldon H., Gleadle J.M., et al. MicroRNA-10b and breast cancer metastasis. Nature 2008, 455:E8-E9. author reply E9.
36. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
37. Green S.K., Francia G., Isidoro C., Kerbel R.S. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-159.
38. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
39. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
40. Hermann P.C., Bhaskar S., Cioffi M., Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010, 20:77-84.
41. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 2006, 118:290-301.
42. Huber M.A., Azoitei N., Baumann B., Grunert S., Sommer A., Pehamberger H., et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004, 114:569-581.
43. Hui A.B., Shi W., Boutros P.C., Miller N., Pintilie M., Fyles T., et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009, 89:597-606.
44. Hulit J., Suyama K., Chung S., Keren R., Agiostratidou G., Shan W., et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007, 67:3106-3116.
45. Iseri O.D., Kars M.D., Arpaci F., Atalay C., Pak I., Gunduz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 2010, 65:40-45.
46. Iwatsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010, 101:293-299.
47. Johansson K.A., Grapin-Botton A. Development and diseases of the pancreas. Clin Genet 2002, 62:14-23.
48. Josson S., Nomura T., Lin J.-T., Huang W.-C., Wu D., Zhau H.E., et al. β-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011, 71:2600-2610.
49. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007, 31:277-283.
50. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
51. Kim M.R., Choi H.-K., Cho K.B., Kim H.S., Kang K.W. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Science 2009, 100:1834-1841.
52. Konecny G.E., Venkatesan N., Yang G., Dering J., Ginther C., Finn R., et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008, 98:1076-1084.
53. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:e1000121.
54. Kumar A., Xu J., Brady S., Gao H., Yu D., Reuben J., et al. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5:e13390.
55. Lebret S.C., Newgreen D.F., Thompson E.W., Ackland M.L. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007, 9:R19.
56. Li Q.-Q., Xu J.-D., Wang W.-J., Cao X.-X., Chen Q., Tang F., et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009, 15:2657-2665.
57. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
58. Li Y., Kong D., Wang Z., Sarkar F.H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010, 27:1027-1041.
59. Li Y., Li W., Yang Y., Lu Y., He C., Hu G., et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009, 1286:13-18.
60. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226.
61. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360.
62. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
63. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
64. Marcato P., Dean C.A., Giacomantonio C.A., Lee P.W. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther 2009, 17:972-979.
65. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., et al. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
66. Martin T.A., Goyal A., Watkins G., Jiang W.G. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005, 12:488-496.
67. Massaguè J. TGFbeta in cancer. Cell 2008, 134:215-230.
68. McConkey D.J., Choi W., Marquis L., Martin F., Williams M.B., Shah J., et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28:335-344.
69. Mego M., Mani S.A., Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 2010, 7:693-701.
70. Melkamu T., Zhang X., Tan J., Zeng Y., Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31:252-258.
71. Mironchik Y., Winnard P.T., Vesuna F., Kato Y., Wildes F., Pathak A.P., et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005, 65:10801-10809.
72. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
73. Moreno-Bueno G., Portillo F., Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969.
74. Ozdamar B., Bose R., Barrios-Rodiles M., Wang H.R., Zhang Y., Wrana J.L. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307:1603-1609.
75. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
76. Perez-Pomares J.M., Munoz-Chapuli R. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in Metazoans. Anat Rec 2002, 268:343-351.
77. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273.
78. Radisky D.C., LaBarge M.A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512.
79. Radisky E.S., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:201-212.
80. Ravatn R., Wells V., Nelson L., Vettori D., Mallucci L., Chin K.V. Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine. Cancer Res 2005, 65:1631-1634.
81. Reuben J.M., Lee B.N., Li C., Gao H., Broglio K.R., Valero V., et al. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J 2010, 16:327-330.
82. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B., Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27:5124-5131.
83. Roussos E.T., Keckesova Z., Haley J.D., Epstein D.M., Weinberg R.A., Condeelis J.S. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 2010, 70:7360-7364.
84. Santisteban M., Reiman J.M., Asiedu M.K., Behrens M.D., Nassar A., Kalli K.R., et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009, 69:2887-2895.
85. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997.
86. Seth P., Wang Z.G., Pister A., Zafar M.B., Kim S., Guise T., et al. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 2006, 17:1152-1160.
87. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007, 14:3629-3637.
88. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
89. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
90. Shook D., Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 2003, 120:1351-1383.
91. Short J.J., Curiel D.T. Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther 2009, 8:2096-2102.
92. Sun M., Estrov Z., Ji Y., Coombes K.R., Harris D.H., Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008, 7:464-473.
93. Tanimizu N., Miyajima A. Molecular mechanism of liver development and regeneration. Int Rev Cytol 2007, 259:1-48.
94. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., et al. Core epithelial-to-mesenchymal transition interactive gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010, 107:15449-15454.
95. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
96. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15:740-746.
97. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
98. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142.
99. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11:213.
100. Trimboli A.J., Fukino K., de Bruin A., Wei G., Shen L., Tanner S.M., et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008, 68:937-945.
101. Tsang W.P., Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010, 21:140-146.
102. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43.
103. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
104. Wang J., Kuiatse I., Lee A.V., Pan J., Giuliano A., Cui X. Sustained c-jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010, 8:266-277.
105. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006, 66:2778-2784.
106. Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010, 13:109-118.
107. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009, 69:2400-2407.
108. Winquist R.J., Boucher D.M., Wood M., Furey B.F. Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine. Biochem Pharmacol 2009, 78:326-334.
109. Wright J.A., Richer J.K., Goodall G.J. MicroRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:213-223.
110. Xue C., Plieth D., Venkov C., Xu C., Neilson E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 2003, 63:3386-3394.
111. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
112. Yang A.D., Fan F., Camp E.R., van Buren G., Liu W., Somcio R., et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006, 12:4147-4153.
113. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
114. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829.
115. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
116. Zardawi S.J., O'Toole S.A., Sutherland R.L., Musgrove E.A. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 2009, 24:385-398.
117. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119:1429-1437.
118. Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008, 283:31079-31086.
119. Zhuo W., Wang Y., Zhuo X., Zhang Y., Ao X., Chen Z. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer 2008, 62:8-14.
120. Zhuo W.L., Wang Y., Zhuo X.L., Zhang Y.S., Chen Z.T. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun 2008, 369:1098-1102.